TOI

The Oncology Institute Announces Third Quarter 2022 Earnings Release Date and Conference Call

Retrieved on: 
Wednesday, October 19, 2022
LLC, GLOBE, NASDAQ, Patient, Eastern Time Zone, American Oncology Institute, Population, TOI, Medical imaging

The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562.

Key Points: 
  • The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562.
  • A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671.
  • Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting.
  • With 90+ employed clinicians and more than 700 teammates in over 50 clinic locations and growing, TOI is changing oncology for the better.

The Oncology Institute Executives to Speak at Key Industry Conferences in Q4

Retrieved on: 
Monday, October 17, 2022
EOM, Lessons learned, Growth, Population, Total, Conference, American Oncology Institute, Wall Street, NASDAQ, Patient, Capital market, OCM, Primary care, Industry, Association, TOI, Innovation, GLOBE, Medicine, Pharmaceutical industry

CERRITOS, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, announced its executives' participation in upcoming key industry conferences.

Key Points: 
  • CERRITOS, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, announced its executives' participation in upcoming key industry conferences.
  • TOIs CEO Brad Hively welcomed the opportunities, commenting, "We look forward to exchanging ideas about how to advance oncology.
  • Now more than ever, the healthcare industry is positioned to provide cutting-edge oncology care while reducing inefficiencies.
  • TOI President Dr. Daniel Virnich will speak at the Reuters Oncology at Total Health 2022 Conference in Chicago, Illinois.

The Oncology Institute Announces New Leaders to Oversee Technology and Clinical Trials

Retrieved on: 
Tuesday, October 11, 2022
Physician, Population, American Oncology Institute, NASDAQ, Patient, Research, Health equity, Radiology, Artificial intelligence, Technology, Data management, Health, TOI, DaVita Inc., GLOBE, Clinical research, CTO, Leadership, Management, Medical imaging

Phil Reger will serve as the Chief Information Officer and Cristina Green will serve as the Vice President of Clinical Research.

Key Points: 
  • Phil Reger will serve as the Chief Information Officer and Cristina Green will serve as the Vice President of Clinical Research.
  • Green will oversee the clinical research arm of TOI and expand access to clinical trials for TOI patients.
  • Most recently, she held roles at Labcorp Drug Development spearheading transformational initiatives for the conduct of clinical trials, including mobile health, decentralized clinical trials, and other study design innovations via data, technology, and process optimization.Ms.
  • Founded in 2007, The Oncology Institute of Hope and Innovation (TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting.

The Oncology Institute Expands into South Florida

Retrieved on: 
Thursday, October 6, 2022
Risk, SEC, Oncology, Population, American Oncology Institute, NASDAQ, Patient, Research, Partnership, Private Securities Litigation Reform Act, Probability, Acquisition, Health, TOI, GLOBE, Forward-looking statement, COVID-19, Medicine, Medical imaging, Plantation

CERRITOS, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based community oncology groups in the United States, announced its entrance into South Florida with the acquisition of Broward Oncology Associates located in Fort Lauderdale and the opening of a new clinic in Plantation.

Key Points: 
  • CERRITOS, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based community oncology groups in the United States, announced its entrance into South Florida with the acquisition of Broward Oncology Associates located in Fort Lauderdale and the opening of a new clinic in Plantation.
  • There may be additional risks that The Oncology Institute presently does not know or that The Oncology Institute currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements.
  • The Oncology Institute anticipates that subsequent events and developments will cause The Oncology Institutes assessments to change.
  • The Oncology Institute does not undertake any obligation to update any of these forward-looking statements.

The Oncology Institute Enrolls Nation’s First Two Patients in a Phase 3 Open-Label, Randomized Clinical Trial of Pirtobrutinib

Retrieved on: 
Thursday, September 29, 2022
BTK, Ibrutinib, Medical director, FDA, Principal, Company, Population, American Oncology Institute, Patient, Clinical trial, Tyrosine kinase, Founder, CLL, NASDAQ, Research, GLOBE, TOI, Eli Lilly, Principal investigator, Pharmaceutical industry, Medical device, Medical imaging

Pirtobrutinib (LOXO-305) is currently in clinical trial phase, whereas Ibrutinib has been available in the market since 2013.

Key Points: 
  • Pirtobrutinib (LOXO-305) is currently in clinical trial phase, whereas Ibrutinib has been available in the market since 2013.
  • Eli Lilly and Company serves as the sponsor of this clinical trial.
  • Pirtobrutinib and Ibrutinib are both oral treatments that bind to the Bruton Tyrosine Kinase (BTK) protein to inhibit its activity.
  • We at TOI are extremely proud of our role in this important clinical trial, says Dr. Yale Podnos, Chief Medical Officer of The Oncology Institute.

The Oncology Institute Appoints Two New Board Members

Retrieved on: 
Thursday, September 22, 2022
Bachelor of Arts in Applied Psychology, Business administration, The Co Founder, Partner, Population, General Catalyst, Marriott Corporation, Harvard Business School, Industry, Hamilton College, American Oncology Institute, Parsons, Patient, Investment, Master of Business Administration, CEO, Technology, The Walt Disney Company, Oak Hill Capital Partners, Board of directors, Yale University, NASDAQ, Board, Forum Group, TOI, GLOBE, Cigna, General Atlantic, Management, Toy, Oracle

CERRITOS, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based community oncology groups in the United States, today announced the appointment of Mark Pacala and Gabe Ling to serve on its Board of Directors (Board), effective immediately.

Key Points: 
  • CERRITOS, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based community oncology groups in the United States, today announced the appointment of Mark Pacala and Gabe Ling to serve on its Board of Directors (Board), effective immediately.
  • We are very pleased to have Mark and Gabe join our Board of Directors, said Brad Hively, Chief Executive Officer of TOI.
  • As TOI continues to expand and mature as a public company, we are excited to attract new talent to our board.
  • Mr. Ling has led investments in companies including The Oncology Institute, Acclivity Health, Dependable Health Services, YAPI, and RHI Group.

Edita Prima: 163-year-old Nordic tech company launches "Talks of imperfection" podcast to lead the global conversation of softer business values

Retrieved on: 
Tuesday, September 20, 2022
Empathy, TOI, Grand & Toy, Marketing, Tourism, Creative industries

Edita Prima, the kindest Nordic tech company based in Helsinki, Finland, believes it does, but only if done differently with a gentle touch of empathy and diversity.

Key Points: 
  • Edita Prima, the kindest Nordic tech company based in Helsinki, Finland, believes it does, but only if done differently with a gentle touch of empathy and diversity.
  • "Talks of imperfection (TOI)is not your ordinary business podcast but a platform for meaningful conversations that help our audiences redefine their views on doubt and vulnerability.
  • We hope our global listeners will feel more comfortable embracing their imperfections and strive for personal growth," says Ville Immonen, Edita Prima's Head of Sales and Marketing.
  • Edita Prima, a tech company with a unique heritage that reaches to 1859, orchestrates automated customer journeys to perfection.

Edita Prima: 163-year-old Nordic tech company launches "Talks of imperfection" podcast to lead the global conversation of softer business values

Retrieved on: 
Tuesday, September 20, 2022
Empathy, TOI, Grand & Toy, Marketing, Tourism, Creative industries

Edita Prima, the kindest Nordic tech company based in Helsinki, Finland, believes it does, but only if done differently with a gentle touch of empathy and diversity.

Key Points: 
  • Edita Prima, the kindest Nordic tech company based in Helsinki, Finland, believes it does, but only if done differently with a gentle touch of empathy and diversity.
  • "Talks of imperfection (TOI)is not your ordinary business podcast but a platform for meaningful conversations that help our audiences redefine their views on doubt and vulnerability.
  • We hope our global listeners will feel more comfortable embracing their imperfections and strive for personal growth," says Ville Immonen, Edita Prima's Head of Sales and Marketing.
  • Edita Prima, a tech company with a unique heritage that reaches to 1859, orchestrates automated customer journeys to perfection.

The Oncology Institute to Participate at the Nephron 2nd Annual Physician Enablement Symposium

Retrieved on: 
Thursday, September 15, 2022
GLOBE, TOI, Population, Patient, Nephron, American Oncology Institute, NASDAQ, Pharmaceutical industry, Medical imaging

CERRITOS, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that its Chief Executive Officer, Brad Hively, will participate on the Next Frontier - Value Based Care for Sub-Capitation/Specialties panel at the Nephron 2nd Annual Physician Enablement Symposium on Thursday, September 22 at 9:00am EST.

Key Points: 
  • CERRITOS, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that its Chief Executive Officer, Brad Hively, will participate on the Next Frontier - Value Based Care for Sub-Capitation/Specialties panel at the Nephron 2nd Annual Physician Enablement Symposium on Thursday, September 22 at 9:00am EST.
  • Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting.
  • TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.7 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations.
  • With 90+ employed clinicians and more than 700 teammates in over 50 clinic locations and growing, TOI is changing oncology for the better.

The Oncology Institute Becomes Certified as a Patient Safety Organization

Retrieved on: 
Monday, September 12, 2022
Culture, Safety, Incidence, AHRQ, PSO, Feedback, Population, Compliance, Health, American Oncology Institute, Patient, Certification, NASDAQ, GLOBE, TOI, Agency for Healthcare Research and Quality, Medicine

CERRITOS, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based community oncology groups in the United States, announced today an important step in maximizing patient safety by becoming an Agency for Healthcare Research and Quality accredited Patient Safety Organization (PSO).

Key Points: 
  • CERRITOS, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based community oncology groups in the United States, announced today an important step in maximizing patient safety by becoming an Agency for Healthcare Research and Quality accredited Patient Safety Organization (PSO).
  • The TOI PSO is a newly formed component entity whose purpose is to maintain the highest standards in patients safety and quality by analyzing patient safety data to provide feedback, guidance, and training of TOI clinicians.
  • "At TOI, the quality of our patient care is our highest priority.
  • We believe this certificationwill further demonstrate to our patients that we offerthemthehighest qualitycare, said Dr. Yale Podnos, Chief Medical Officer of The Oncology Institute.